Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/00
출원번호
US-0683114
(2010-01-06)
등록번호
US-8110657
(2012-02-07)
발명자
/ 주소
Kaumaya, Pravin
출원인 / 주소
The Ohio State University
대리인 / 주소
Calfee, Halter & Griswold LLP
인용정보
피인용 횟수 :
3인용 특허 :
14
초록▼
Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present inventio
Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also provided are pharmaceutical compositions comprising such immunogenic compositions. Methods for stimulating an immune response to HER-2 protein are provided. Methods for treating breast cancer, ovarian cancer, prostate cancer, colon cancer and lung cancer are provided.
대표청구항▼
1. A chimeric peptide for stimulating an immune response to HER-2 protein comprising a HER-2 B cell epitope, a T helper (Th) epitope, and a linker joining the HER-2 B cell epitope to the Th epitope, wherein: the HER-2 B cell epitope consists of a sequence selected from the group consisting of: ALVTY
1. A chimeric peptide for stimulating an immune response to HER-2 protein comprising a HER-2 B cell epitope, a T helper (Th) epitope, and a linker joining the HER-2 B cell epitope to the Th epitope, wherein: the HER-2 B cell epitope consists of a sequence selected from the group consisting of: ALVTYNTDTFESMPNPEGRYT,SEQ ID NO: 5;the Th epitope comprises a sequence selected from the group consisting of: NSVDDALINSTIYSYFPSV,SEQ ID NO: 13;PGINGKAIHLVNNQSSE,SEQ ID NO: 14;QYIKANSKFIGITEL,SEQ ID NO: 15;NNFTVSFWLRVPKVSASHLE,SEQ ID NO: 16;LSEIKGVIVHRLEGV,SEQ ID NO: 17;FFLLTRILTIPQSLN,SEQ ID NO: 18;andTCGVGVRVRSRVNAANKKPE,SEQ ID NO: 19;andthe linker comprises a sequence that is from 1 to 15 amino acids in length. 2. The chimeric peptide of claim 1 wherein the Th epitope comprises NSVDDALINSTIYSYFPSV, SEQ ID NO: 13. 3. The chimeric peptide of claim 1 wherein the Th epitope comprises PGINGKAIHLVNNQSSE, SEQ ID NO: 14. 4. The chimeric peptide of claim 1 wherein the Th epitope comprises QYIKANSKFIGITEL, SEQ ID NO: 15. 5. The chimeric peptide of claim 1 wherein the Th epitope comprises FNNFTVSFWLRVPKVSASHLE, SEQ ID NO: 16. 6. The chimeric peptide of claim 1 wherein the Th epitope comprises LSEIKGVIVHRLEGV, SEQ ID NO: 17. 7. The chimeric peptide of claim 1 wherein the Th epitope comprises FFLLTRILTIPQSLN, SEQ ID NO: 18. 8. The chimeric peptide of claim 1 wherein the Th epitope comprises TCGVGVRVRSRVNAANKKPE, SEQ ID NO: 19. 9. The chimeric peptide of claim 1 wherein the linker comprises a sequence that is from 2 to 15 amino acids in length. 10. The chimeric peptide of claim 9 wherein the linker comprises GPSL, SEQ ID NO: 20. 11. The chimeric peptide of claim 1 further comprising a second HER-2 B cell epitope comprising a sequence selected from the group consisting of: TGTDMKLRLPASPETHLDM,SEQ ID NO: 1;AVLDNGDPLNNTTPVTGASPGG,SEQ ID NO: 2;LWKDIFHKINNQLALTLIDTNRS,SEQ ID NO: 3;TLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLT,SEQ ID NO: 4;ALVTYNTDTFESMPNPEGRYT,SEQ ID NO: 5;PLHNQEVTAEDGTQRAEKCSKPCA,SEQ ID NO: 6;PESFDGDPASNTAPLQPE,SEQ ID NO: 7;LYISAWPDSLPDLSVFQNLQ,SEQ ID NO: 8;LFRNPHQALLHTANRPEDE,SEQ ID NO: 9;CLPCHPECQPQNGSVTCFGPEADQCVACAHYKDP,SEQ ID NO: 10;KPDLSYMPIWKFPDEEGA,SEQ ID NO: 11;andINGTHSCVDLDDKGCPAEQRAS,SEQ ID NO: 12. 12. The chimeric peptide of claim 11 further comprising a second linker joining the first HER-2 B cell epitope to the second HER-2 B cell epitope. 13. The chimeric peptide of claim 12 wherein the second linker comprises a sequence that is from 1 to 15 amino acids in length. 14. The chimeric peptide of claim 13 wherein the second linker comprises GPSL, SEQ ID NO: 20. 15. An immunogenic composition comprising a chimeric peptide of claim 1 or claim 11.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (14)
Kaumaya, Pravin, Chimeric peptides comprising HER-2 B-cell epitopes and measles virus fusion protein T-cell epitopes.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is a.
Cheever Martin A. (Mercer Island WA) Peace David J. (Seattle WA), Immune reactivity to expressed activated oncogenes for diagnosis and treatment of malignancy.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.